Dermata Therapeutics (Dermata Therapeutics) Cash-to-Debt : No Debt ⁽¹⁾ (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Dermata Therapeutics Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Dermata Therapeutics's cash to debt ratio for the quarter that ended in Mar. 2024 was No Debt ⁽¹⁾.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Dermata Therapeutics could pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.

(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Dermata Therapeutics's Cash-to-Debt or its related term are showing as below:

DRMA' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.15 Med: No Debt Max: No Debt
Current: No Debt

During the past 5 years, Dermata Therapeutics's highest Cash to Debt Ratio was No Debt. The lowest was 0.15. And the median was No Debt.

DRMA's Cash-to-Debt is ranked better than
99.8% of 1478 companies
in the Biotechnology industry
Industry Median: 7.005 vs DRMA: No Debt

Dermata Therapeutics Cash-to-Debt Historical Data

The historical data trend for Dermata Therapeutics's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Dermata Therapeutics Cash-to-Debt Chart

Dermata Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

1.55

0.15

No Debt

Dermata Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash-to-Debt	Get a 7-Day Free Trial													No Debt	No Debt	No Debt	No Debt	No Debt

Competitive Comparison of Dermata Therapeutics's Cash-to-Debt

For the Biotechnology subindustry, Dermata Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Dermata Therapeutics's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Dermata Therapeutics's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Dermata Therapeutics's Cash-to-Debt falls into.

Dermata Therapeutics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Dermata Therapeutics's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Dermata Therapeutics had no debt ⁽¹⁾.

Dermata Therapeutics's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:

Dermata Therapeutics had no debt ⁽¹⁾.

Dermata Therapeutics (NAS:DRMA) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Dermata Therapeutics Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Dermata Therapeutics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Dermata Therapeutics (Dermata Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dermata Therapeutics Inc (NAS:DRMA) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

3525 Del Mar Heights Road, Suite No. 322, San Diego, CA, USA, 92130

Website

https://www.dermatarx.com

Dermata Therapeutics Inc is a clinical-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its two product candidates, DMT310 and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to develop and formulate singular and combination products that are able to target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases.

Executives

Brittany Bradrick	director	C/O DERMATA THERAPEUTICS, INC., 3525 DEL MAR HEIGHTS RD., #322, SAN DIEGO CA 92130
Gerald T Proehl	10 percent owner, officer: Pres., CEO and Chairman
Van Hoose Kyri K.	officer: Chief Financial Officer	C/O TURNING POINT THERAPEUTICS, INC., 10628 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO CA 92121
Mary Fisher	director	C/O ACORDA THERAPEUTICS, INC., 15 SKYLINE DRIVE, HAWTHORNE NY 10532
David F Hale	director	1042-B NORTH EL CAMINO REAL, SUITE 430, ENCINITAS CA 92024
Steven J Mento	director	C/O SANGAMO BIOSCIENCES, INC., 501 CANAL BLVD SUITE A-100, RICHMOND CA 94804
Wendell Wierenga	director	C/O CIPHERGEN BIOSYSTEMS INC, 6611 DUMBARTON CIRCLE, FREMONT CA 94555
Kathleen D. Scott	director	C/O CONATUS PHARMACEUTICALS INC., 16745 WEST BERNARDO DRIVE, SUITE 200, SAN DIEGO CA 92127
Thomas Insley	officer: Chief Financial Officer	SKINMEDICA, INC., 5909 SEA LION PLACE, SUITE H, CARLSBAD CA 92010
Bedoya-toro Munera Maria E	officer: Senior VP	10590 WEST OCEAN AIR DRIVE, SUITE 200, SAN DIEGO CA 92130
Andrew Seth Sandler	director	1301 2ND AVE, SEATTLE WA 98101
Christopher J. Nardo	officer: Senior VP, Development	C/O DERMATA THERAPEUTICS, INC., 3525 DEL MAR HEIGHTS RD., #322, SAN DIEGO CA 92130
Proehl Investment Ventures Llc	10 percent owner	C/O DERMATA THERAPEUTICS, INC., 3525 DEL MAR HEIGHTS RD., #332, SAN DIEGO CA 92130